Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Clinical benefit seen with SOR-007 in patients with cutaneous metastases

Dec. 16, 2020

PRDM2, a novel SMAD3-dependent immunosuppressor for promoting NSCLC

Dec. 16, 2020

SMAD3 as new therapeutic target for NSCLC

Dec. 16, 2020

Voronoi discloses new RET inhibitors

Dec. 16, 2020

Phase I results show safety and activity with rintodestrant in ER+/HER2- breast cancer

Dec. 16, 2020

Lantern announces promising preclinical data for LP-184 in GBM

Dec. 16, 2020

Verastem initiates phase II registration-directed study of VS-6766 plus defactinib in NSCLC

Dec. 16, 2020

Cancer Research UK approves Teon's TT-702 for clinical collaboration

Dec. 16, 2020

BioTheryX presents new GSPT1 inhibitors

Dec. 15, 2020

Gilead Sciences identifies MAP4K1 inhibitors

Dec. 15, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026